PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24113148-5 2013 Furthermore, the distribution of sunitinib to the brain increased after administration of selective P-glycoprotein (P-gp) or breast cancer resistance protein (Bcrp) pharmacological inhibitors and a dual inhibitor, elacridar, comparable to that of the corresponding transgenic genotype. Sunitinib 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 125-157 24113148-5 2013 Furthermore, the distribution of sunitinib to the brain increased after administration of selective P-glycoprotein (P-gp) or breast cancer resistance protein (Bcrp) pharmacological inhibitors and a dual inhibitor, elacridar, comparable to that of the corresponding transgenic genotype. Sunitinib 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 159-163 22673043-7 2012 The maximum concentration and AUC(0-4) of sunitinib were significantly higher in Abcg2(-/-), Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice than wild-type mice when sunitinib was given orally but not intraperitoneally. Sunitinib 42-51 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 81-86 23843632-0 2013 Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. Sunitinib 169-178 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 71-76 22238213-0 2012 P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. Sunitinib 110-119 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 61-66 22238213-7 2012 In the absence of the ABCB1 and ABCG2 inhibitor elacridar, brain concentrations of N-desethyl sunitinib were detectable only in Abcb1a/1b(-/-)/Abcg2(-/-) mice after sunitinib administration. Sunitinib 94-103 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 143-148 22673043-7 2012 The maximum concentration and AUC(0-4) of sunitinib were significantly higher in Abcg2(-/-), Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice than wild-type mice when sunitinib was given orally but not intraperitoneally. Sunitinib 42-51 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 122-127 30953637-8 2019 Moreover, the combination of SN-38 and sunitinib caused synergism on colon cancer cells, with significant inhibition of the ABCG2 gene expression and an increase of SN-38 intracellular concentrations. Sunitinib 39-48 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 124-129 21351087-0 2012 Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Sunitinib 22-31 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 110-115 21351087-2 2012 We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar. Sunitinib 169-178 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 105-110 21351087-2 2012 We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar. Sunitinib 213-222 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 105-110 21351087-2 2012 We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar. Sunitinib 213-222 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 278-283 21351087-4 2012 In vitro, sunitinib was a good substrate of murine (mu)ABCG2 and a moderate substrate of human (hu)ABCB1 and huABCG2. Sunitinib 10-19 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 55-60 21351087-6 2012 Brain accumulation of sunitinib was markedly (23-fold) increased in Abcb1a/b/Abcg2(-/-) mice, but only slightly (2.3-fold) in Abcb1a/b(-/-) mice, and not in Abcg2(-/-) mice. Sunitinib 22-31 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 77-82 21351087-6 2012 Brain accumulation of sunitinib was markedly (23-fold) increased in Abcb1a/b/Abcg2(-/-) mice, but only slightly (2.3-fold) in Abcb1a/b(-/-) mice, and not in Abcg2(-/-) mice. Sunitinib 22-31 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 159-164 21351087-7 2012 Importantly, a clinically realistic coadministration of oral elacridar and oral sunitinib to wild-type mice resulted in markedly increased sunitinib brain accumulation, equaling levels in Abcb1a/1b/Abcg2(-/-) mice. Sunitinib 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 198-203 21309545-8 2011 Furthermore, sunitinib was transported equally by ABCB1 and ABCG2 at low concentrations, but ABCG2-mediated transport became saturated at lower concentrations than ABCB1-mediated transport. Sunitinib 13-22 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 60-65 27495788-1 2016 PURPOSE: Pharmacokinetic interaction of sunitinib with diclofenac, paracetamol, mefenamic acid and ibuprofen was evaluated due to their P450 mediated metabolism and OATP1B1, OATP1B3, ABCB1, ABCG2 transporters overlapping features. Sunitinib 40-49 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 190-195 26011058-1 2015 Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC, and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate. Sunitinib 26-35 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 152-157 25663899-6 2015 Functionally, the role of ABCG2 in the resistance to sunitinib was confirmed by the use of the ABCG2 inhibitors fumitremorgin C and diethylstilbestrol, which blocked cell resistance. Sunitinib 53-62 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 26-31 25663899-6 2015 Functionally, the role of ABCG2 in the resistance to sunitinib was confirmed by the use of the ABCG2 inhibitors fumitremorgin C and diethylstilbestrol, which blocked cell resistance. Sunitinib 53-62 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 95-100